Skip to main content

Newsroom press releases

22/12/25 - 17:25

2026 Annual Corporate Events Calendar (117.34 KB)
Other

22/12/25 - 14:36

The Board of Directors approved to submit to the Shareholders' Meeting the authorization for the purchase and cancellation of treasury shares for the purpose of shareholder remuneration. Ordinary and extraordinary shareholders' meeting convened. (125.84 KB)
Other

24/11/25 - 11:10

Diasorin submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance (128.44 KB)
Products Molecular

18/11/25 - 6:30

Diasorin, in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark (147.94 KB)
Products Immunodiagnostic

05/11/25 - 17:46

Diasorin’s Board of Directors approves results for the first 9 months of 2025. FY 2025 Guidance revised (255.77 KB)
Financial Data

31/10/25 - 10:12

Diasorin receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration (132.55 KB)
Products Molecular

22/10/25 - 7:41

Diasorin signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX (125.42 KB)
Molecular

19/09/25 - 9:34

Diasorin launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark (130.17 KB)
Products Immunodiagnostic

08/09/25 - 11:16

New evidence on MeMed BV's role in supporting emergency medicine clinical decisions unveiled at ACEP 2025 (136.64 KB)
Products Immunodiagnostic

31/07/25 - 16:22

Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed (238.17 KB)
Financial Data

02/07/25 - 8:10

Diasorin submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver (133.82 KB)
Products Molecular

07/06/25 - 12:25

Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (143.05 KB)
Products Molecular

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)
Financial Data

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)
Products

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)
Products Molecular

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)
Financial Data

17/12/24 - 12:56

2025 Annual Calendar of Corporate Events (104.79 KB)

11/11/24 - 7:38

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)
Products Molecular

05/11/24 - 16:27

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)
Financial Data

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)
Products Molecular

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)
Products Immunodiagnostic

05/09/24 - 11:17

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)
Other

04/09/24 - 11:36

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)
Other

29/07/24 - 15:55

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)
Financial Data

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)
Products Molecular

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)
Products Molecular

16/05/24 - 19:56

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)
Products Molecular

10/05/24 - 15:21

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)
Financial Data

24/04/24 - 15:38

Shareholders' Meeting 2024 (159.72 KB)
Other

16/04/24 - 8:20

Communication on total amount of voting rights (135.47 KB)
Other

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
Financial Data

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)
Products Molecular

03/03/24 - 19:32

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)
Products Molecular

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)
Products Immunodiagnostic

15/12/23 - 17:38

Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
Financial Data

06/11/23 - 15:44

Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
Products Immunodiagnostic

03/11/23 - 15:51

Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
Financial Data

24/10/23 - 15:03

Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)
Other

27/07/23 - 14:27

Update 2023 Annual Calendar of Corporate Events (104.1 KB)
Other

27/07/23 - 13:18

Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
Financial Data

17/07/23 - 7:03

DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
Products Immunodiagnostic

03/07/23 - 11:48

Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)
Other

13/06/23 - 15:18

DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
Products Immunodiagnostic

07/06/23 - 14:40

Communication of total amount of voting rights (7 June 2023) (141.14 KB)
Financial Disclosures

05/06/23 - 21:58

Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)
Other

26/05/23 - 7:10

DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)
Acquisition / Partnership

09/05/23 - 11:56

Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
Financial Data

28/04/23 - 12:52

Shareholders' Meeting 2023 (373.48 KB)
Other

27/03/23 - 15:52

Update 2023 Annual Calendar of Corporate Events (483.89 KB)
Financial Disclosures

27/03/23 - 14:38

Dividend coupon date correction (493.46 KB)
Financial Data

27/03/23 - 13:35

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
Financial Data

17/03/23 - 22:05

DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
Products Molecular

28/02/23 - 16:06

Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)
Acquisition / Partnership

13/02/23 - 22:03

CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)
Acquisition / Partnership

07/02/23 - 12:01

Update 2023 Annual Calendar of Corporate Events (288.3 KB)
Financial Disclosures

01/12/22 - 18:30

2023 Annual Calendar of Corporate Events (288 KB)
Other

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products Molecular

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products Molecular

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products Molecular

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products Molecular

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products Immunodiagnostic

07/06/22 - 18:06

Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
Other

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products Molecular

09/05/22 - 7:02

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
Acquisition / Partnership

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)
Financial Disclosures

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)
Financial Disclosures

29/04/22 - 16:26

Shareholders' meeting 2022 (166.12 KB)
Other

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
Financial Disclosures

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
Financial Disclosures

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
Financial Disclosures

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)
Financial Disclosures

05/04/22 - 9:51

Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
Other

04/04/22 - 18:12

Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
Other

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products Molecular

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products Molecular

21/12/21 - 11:07

2022 Annual Calendar of Corporate Events (296.13 KB)
Other

16/12/21 - 22:47

DiaSorin 2022-2025 Strategic Plan (552.15 KB)
Financial Data

30/11/21 - 19:10

DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)
Products Molecular

29/11/21 - 7:06

DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)
Products Immunodiagnostic

23/11/21 - 7:10

DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)
Products Immunodiagnostic

11/11/21 - 16:56

DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)
Financial Data

05/11/21 - 11:22

Weekly report treasury shares buy-back (2.15 MB)
Other

02/11/21 - 20:00

Conclusion treasury shares buy-back plan (294.67 KB)
Other

02/11/21 - 19:57

Weekly report treasury shares buy-back (3.5 MB)
Other

27/10/21 - 16:35

Issuance of the "Physical Settlement Notice" (517.5 KB)
Other

07/10/21 - 11:45

Publication of the summary report of the votes (290.08 KB)
Other

04/10/21 - 12:27

The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase (297.73 KB)
Other

18/09/21 - 8:16

DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)
Products Molecular

30/07/21 - 18:43

Start up of the treasury shares buy-back plan (773.96 KB)
Other

30/07/21 - 12:57

DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)
Financial Data

22/07/21 - 18:28

Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999 (303.95 KB)
Other

14/07/21 - 15:05

DiaSorin announces completion of the Acquisition of Luminex Corporation (566.52 KB)
Acquisition / Partnership

09/07/21 - 7:34

DiaSorin obtains all approvals necessary to complete the acquisition of Luminex (560.68 KB)
Acquisition / Partnership

21/06/21 - 18:49

The Shareholders’ meeting of Luminex Corporation approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin (395.62 KB)
Acquisition / Partnership

15/06/21 - 6:56

DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)
Products Immunodiagnostic

07/06/21 - 15:16

Communication on total amount of voting rights (563.42 KB)
Other

03/06/21 - 7:47

DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ (523.42 KB)
Acquisition / Partnership

25/05/21 - 7:03

DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)
Products Immunodiagnostic

21/05/21 - 7:02

DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)
Products Molecular

20/05/21 - 8:27

DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)
Products Immunodiagnostic

14/05/21 - 16:10

DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)
Financial Data

28/04/21 - 17:46

DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)
Financial Data

28/04/21 - 7:54

DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)
Financial Data

22/04/21 - 15:58

Shareholders' meeting April 22, 2021 (422.91 KB)
Other

21/04/21 - 7:02

DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)
Products Immunodiagnostic

20/04/21 - 18:58

DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)
Products Immunodiagnostic

14/04/21 - 10:05

Communication voting rights amount (544.6 KB)
Other

12/04/21 - 11:08

Weekly report treasury shares buy-back (914.42 KB)
Other

11/04/21 - 19:47

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion (569.09 KB)
Acquisition / Partnership

06/04/21 - 8:53

Start up buy-back plan (774.02 KB)
Other

06/04/21 - 7:06

DiaSorin announces its strategic collaboration with Lumos Diagnostics (438.14 KB)
Acquisition / Partnership

30/03/21 - 7:01

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)
Products Immunodiagnostic

29/03/21 - 7:02

DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)
Products Immunodiagnostic

11/03/21 - 16:37

Dividend coupon date correction (414.99 KB)
Financial Data

11/03/21 - 15:31

Revenues, Profitability and Cash Flow Generation hit record highs in 2020 (748.06 KB)
Financial Data

23/02/21 - 6:11

DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)
Products Immunodiagnostic

27/01/21 - 18:50

2021 Annual Calendar of Corporate Events (209.87 KB)
Other

11/01/21 - 18:43

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)
Products Immunodiagnostic

29/12/20 - 18:22

DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
Products Molecular

17/12/20 - 17:57

DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics (298.96 KB)
Other

07/12/20 - 10:35

Communication on total amount of voting rights (563.18 KB)
Other

04/12/20 - 16:14

Form 3F (November 2020) (10.2 KB)
Other

01/12/20 - 6:33

DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
Products Immunodiagnostic

11/11/20 - 12:41

North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
Financial Data

26/10/20 - 18:30

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
Products Immunodiagnostic

23/10/20 - 19:41

Conclusion treasury shares buy-back plan (314.28 KB)
Other

23/10/20 - 19:37

Weekly report treasury shares buy-back (436.92 KB)
Other

16/10/20 - 18:28

Weekly report treasury shares buy-back (425.19 KB)
Other

01/10/20 - 7:45

DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
Products Immunodiagnostic

01/10/20 - 7:32

DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
Products Immunodiagnostic

23/09/20 - 7:16

DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China (495.78 KB)
Acquisition / Partnership

16/09/20 - 14:30

Update Annual Calendar of Corporate Events 2020 (222.26 KB)
Other

16/09/20 - 7:25

DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
Products Molecular

08/09/20 - 7:31

DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution (506.16 KB)
Acquisition / Partnership

07/09/20 - 18:22

FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
Products Molecular

06/08/20 - 7:25

DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
Products Immunodiagnostic

31/07/20 - 16:04

Weekly report treasury shares buy-back (380.16 KB)
Other

30/07/20 - 13:16

North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
Financial Data

24/07/20 - 17:19

Weekly report treasury shares buy-back (363.73 KB)
Other

17/07/20 - 18:19

Weekly report treasury shares buy-back (360.09 KB)
Other

10/07/20 - 18:23

Weekly report treasury shares buy-back (374 KB)
Other

09/07/20 - 7:27

DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
Products Immunodiagnostic

07/07/20 - 7:22

DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
Products Molecular

30/06/20 - 7:25

DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
Products Immunodiagnostic

19/06/20 - 17:20

Weekly report treasury shares buy-back (399.38 KB)
Other

17/06/20 - 16:09

Start up of the treasury shares buy-back plan (481.28 KB)
Other

12/06/20 - 7:30

DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
Products Molecular

10/06/20 - 15:40

Shareholders' Meeting June 10, 2020 (308.25 KB)
Other

03/06/20 - 14:16

The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
Products Immunodiagnostic

02/06/20 - 14:58

Communication total amount voting rights (record date) (267.83 KB)

18/05/20 - 11:28

The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
Products Immunodiagnostic

13/05/20 - 13:15

DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
Financial Data

25/04/20 - 16:49

DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
Products Immunodiagnostic

17/04/20 - 18:25

DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
Products Immunodiagnostic

07/04/20 - 7:14

IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
Products Immunodiagnostic

26/03/20 - 18:14

Update Annual Calendar of Corporate Events 2020 (277.25 KB)
Other

21/03/20 - 20:29

Shareholders' Meeting date change (288.23 KB)
Other

20/03/20 - 7:28

DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
Products Molecular

13/03/20 - 17:16

DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
Products Molecular

11/03/20 - 13:43

DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
Financial Data

10/03/20 - 8:20

DiaSorin - Development of Coronavirus test (404.03 KB)
Products Molecular

02/03/20 - 8:04

DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology (396.06 KB)
Acquisition / Partnership

07/02/20 - 8:06

Communication on total amount of voting rights (281.13 KB)
Other

15/01/20 - 16:51

Annual Calendar of Corporate Events 2020 (124.73 KB)
Other

16/12/19 - 14:10

Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
Products Molecular

06/12/19 - 18:12

Press Release (262.61 KB)
Other

06/12/19 - 18:11

Press Release (262.7 KB)
Other

06/12/19 - 18:08

Communication on total amount of voting rights (281.87 KB)
Other

27/11/19 - 7:59

DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
Products Immunodiagnostic

11/11/19 - 9:46

DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
Products Molecular

06/11/19 - 13:00

Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
Financial Data

30/10/19 - 9:55

DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
Products Immunodiagnostic

22/10/19 - 14:10

DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
Products Immunodiagnostic

07/10/19 - 10:20

Communication on total amount of voting rights (282.21 KB)
Other

24/09/19 - 10:10

DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
Products Molecular

31/07/19 - 13:00

DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
Financial Data

10/06/19 - 18:23

DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
Financial Data

05/06/19 - 7:38

DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease (448.98 KB)
Acquisition / Partnership Immunodiagnostic

29/05/19 - 15:06

DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
Products Molecular

09/05/19 - 13:14

DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
Financial Data

06/05/19 - 15:19

DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
Products Immunodiagnostic

30/04/19 - 12:28

Update Annual Calendar of Corporate Events 2019 (249.43 KB)
Other

24/04/19 - 17:24

DiaSorin: Shareholders' Meeting 2019 (449.66 KB)
Other

12/04/19 - 8:59

Communication on total amount of voting rights (320.44 KB)
Other

05/04/19 - 9:33

Communication on total amount of voting rights (342.47 KB)
Other

03/04/19 - 20:18

Lists publication (79.68 KB)
Other

03/04/19 - 10:32

DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
Products Immunodiagnostic

14/03/19 - 14:16

Growth in revenues, profitability and net profit in 2018 (1.03 MB)
Financial Data

07/03/19 - 11:45

Communication on total amount of voting rights (350.08 KB)
Other

06/03/19 - 8:45

A new Group website for DiaSorin: www.diasoringroup.com (154.5 KB)
Other

07/02/19 - 15:15

Communication on total amount of voting rights (February 7, 2019) (349.86 KB)
Other

31/01/19 - 22:30

DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
Products Immunodiagnostic

03/01/19 - 13:30

DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States (428.56 KB)
Products Molecular

21/12/18 - 11:30

DiaSorin launches 3 new primer pairs for use in molecular testing (438.25 KB)
Products Molecular

04/12/18 - 8:00

DiaSorin's stocks listed in the FTSE MIB (464.63 KB)
Financial Data

19/11/18 - 15:00

DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States (435.43 KB)
Products Molecular

07/11/18 - 13:00

DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018 (961.72 KB)
Financial Data

17/10/18 - 11:51

DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market (147.78 KB)
Products Molecular

12/10/18 - 11:47

DiaSorin launches Simplexa VZV Direct molecular assay in the european market (444.81 KB)
Products Molecular

09/10/18 - 11:35

DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom (471.21 KB)
Acquisition / Partnership

17/09/18 - 11:28

DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen (753.85 KB)
Products Immunodiagnostic

07/08/18 - 8:45

Communication on total amount of voting rights (305.24 KB)
Financial Data

02/08/18 - 12:45

The Board of Directors approves the results for the first half of 2018 (883.1 KB)
Financial Data

27/07/18 - 12:00

DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform (735.03 KB)
Products Immunodiagnostic

03/07/18 - 18:30

Conclusion treasury shares buy-back plan (397.33 KB)
Financial Data

03/07/18 - 18:30

Annex 3F (treasury shares buy back July 2018) (6.59 KB)
Financial Data

03/07/18 - 18:30

Report treasury shares buy-back (287.99 KB)
Financial Data

03/07/18 - 18:30

Annex 3F (treasury shares buy back June 2018) (8.69 KB)
Financial Data

29/06/18 - 18:15

Weekly report treasury shares buy-back (290.62 KB)
Financial Data

22/06/18 - 20:30

Weekly report treasury shares buy-back (290.6 KB)
Financial Data

15/06/18 - 21:00

Weekly report treasury shares buy-back (290.62 KB)
Financial Data

12/06/18 - 14:15

DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia (445.17 KB)
Products Molecular

08/06/18 - 23:15

Weekly report treasury shares buy-back (290.24 KB)
Financial Data

04/06/18 - 13:15

Annex 3F (treasury shares buy back May 2018) (8.54 KB)
Financial Data

01/06/18 - 20:15

Weekly report treasury shares buy-back (290.38 KB)
Financial Data

25/05/18 - 22:30

Weekly report treasury shares buy-back (289.97 KB)
Financial Data

19/05/18 - 1:45

Weekly report treasury shares buy-back (289.76 KB)
Financial Data

11/05/18 - 20:15

Weekly report treasury shares buy-back (290.77 KB)
Financial Data

08/05/18 - 14:30

The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018 (832.84 KB)
Financial Data

03/05/18 - 20:15

Start up treasury shares buy-back plan (354.27 KB)
Financial Data

24/04/18 - 14:00

Annex 3F (treasury shares buy back) (7.77 KB)
Financial Data

23/04/18 - 18:30

Annual General Meeting 2018 (589.65 KB)
Financial Data

19/04/18 - 21:15

Conclusion treasury shares buy-back plan (397.59 KB)
Financial Data

19/04/18 - 21:00

Weekly report treasury shares buy-back (289.29 KB)
Financial Data

13/04/18 - 20:30

Weekly report treasury shares buy-back (290.07 KB)
Financial Data

06/04/18 - 19:45

Weekly report treasury shares buy-back (288.33 KB)
Financial Data

05/04/18 - 12:00

DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis) (737.88 KB)
Products Immunodiagnostic

04/04/18 - 20:00

Start up treasury shares buy-back plan (346.04 KB)
Financial Data

28/03/18 - 18:45

DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test (442.69 KB)
Products Molecular

07/03/18 - 15:30

DiaSorin: FY 2017 Results (1.14 MB)
Financial Data

30/01/18 - 11:45

DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime (574.68 KB)
Financial Data

08/01/18 - 9:00

QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
Acquisition / Partnership

08/01/18 - 9:00

QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
Acquisition / Partnership

12/12/17 - 13:15

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
Products Molecular

29/11/17 - 19:30

Resignation of a Strategic Executive of the Company (233.58 KB)
Other

09/11/17 - 14:15

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
Financial Data

29/09/17 - 15:00

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
Financial Data

29/09/17 - 14:15

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)
Acquisition / Partnership

21/09/17 - 12:45

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
Products Molecular

03/08/17 - 14:45

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
Financial Data

28/07/17 - 14:45

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
Products Molecular

25/07/17 - 21:00

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)
Acquisition / Partnership

10/07/17 - 13:30

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
Products Molecular

26/06/17 - 9:45

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
Financial Data

23/06/17 - 9:30

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)
Acquisition / Partnership

22/06/17 - 19:45

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)
Acquisition / Partnership

23/05/17 - 11:45

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
Products Immunodiagnostic

16/05/17 - 13:00

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
Products Immunodiagnostic

08/05/17 - 19:30

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
Financial Data

27/04/17 - 18:45

DiaSorin - Annual General Meeting 2016 (421.04 KB)
Financial Data

21/04/17 - 18:45

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
Products Immunodiagnostic

06/04/17 - 18:00

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
Products Immunodiagnostic

08/03/17 - 15:30

The Board of Directors approves the results for FY'16 (1.13 MB)
Financial Data

21/02/17 - 11:30

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
Products Molecular

26/01/17 - 12:45

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)
Products Immunodiagnostic

19/12/16 - 10:00

Co-optation of a Director (333.18 KB)
Financial Data

10/11/16 - 1:00

DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)
Financial Data

02/11/16 - 1:00

DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)
Products Molecular

30/08/16 - 2:00

DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market (404.63 KB)
Acquisition / Partnership

22/08/16 - 2:00

DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)
Products Immunodiagnostic

04/08/16 - 2:00

The Board of Directors approves results for H1'16 (697.16 KB)
Financial Data

28/07/16 - 2:00

DiaSorin starts selling Vitamin D in Japan (724.4 KB)
Products Immunodiagnostic

14/07/16 - 2:00

DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)
Products Molecular

10/06/16 - 2:00

Weekly report treasury shares buy-back (289.83 KB)
Financial Data

10/06/16 - 2:00

Conclusion buy-back plan (367.77 KB)
Financial Data

07/06/16 - 2:00

DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)
Products Immunodiagnostic

03/06/16 - 2:00

Weekly report treasury shares buy-back (290.21 KB)
Financial Data

30/05/16 - 2:00

Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)
Financial Data

27/05/16 - 2:00

Weekly report treasury shares buy-back (289.34 KB)
Financial Data

20/05/16 - 2:00

Weekly report treasury shares buy-back (290.09 KB)
Financial Data

13/05/16 - 2:00

Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business (350.22 KB)
Acquisition / Partnership

12/05/16 - 2:00

Start up treasury shares buy-back plan (305.9 KB)
Financial Data

09/05/16 - 2:00

The Board of Directors approves the results for Q1'16 (632.78 KB)
Financial Data

28/04/16 - 2:00

Shareholders' Meeting FY 2015 (365.15 KB)
Financial Data

30/03/16 - 2:00

DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business (133.62 KB)
Acquisition / Partnership

09/03/16 - 1:00

The Board of Directors approves the results for FY'15 (785.08 KB)
Financial Data

11/11/15 - 1:00

The Board of Directors approves the results for Q3'15 (778.06 KB)
Financial Data

09/09/15 - 2:00

DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)
Products Molecular

30/07/15 - 2:00

H1'15 Results (777.06 KB)
Financial Data

20/07/15 - 2:00

DiaSorin and Beckman Coulter sign a distribution agreement for China (238.01 KB)
Acquisition / Partnership

28/05/15 - 2:00

DiaSorin launches the test for Campylobacter (241.86 KB)
Products Immunodiagnostic

12/05/15 - 2:00

DiaSorin presents the 2015-2017 industrial plan (305.81 KB)
Other

12/05/15 - 2:00

The Board of Directors approves the results for Q1'15 (553.96 KB)
Financial Data

29/04/15 - 2:00

DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)
Products Immunodiagnostic

23/04/15 - 2:00

DiaSorin supports the Pinocchio Project (251.16 KB)

22/04/15 - 2:00

The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)
Financial Data

22/04/15 - 2:00

Shareholders' meeting approves FY Results 2014 (105.93 KB)
Financial Data

14/04/15 - 2:00

DiaSorin launches the tests for Bordetella pertussis (187.11 KB)
Products Immunodiagnostic

10/04/15 - 2:00

Investor Day-save the date (107.93 KB)
Financial Data

24/03/15 - 1:00

DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation (504.27 KB)

03/03/15 - 1:00

The Board of Directors approves the results for FY'14 (783.03 KB)
Financial Data

24/02/15 - 1:00

DiaSorin supports Emergency in Sudan (612.64 KB)

13/02/15 - 1:00

DiaSorin teams with FISIP for Progetto talenti (612.64 KB)

14/01/15 - 1:00

DiaSorin launches the test for Calprotectin (259.67 KB)
Products Immunodiagnostic

16/12/14 - 1:00

FDA approves 1,25 Vitamin D in the US market (239.73 KB)
Products Immunodiagnostic

09/12/14 - 1:00

DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL (265.26 KB)
Products Immunodiagnostic

14/11/14 - 1:00

The Board of Directors approves the results for Q3'14 (785.42 KB)
Financial Data

07/10/14 - 2:00

DiaSorin launches the test for HIV HT on LIAISON (267.4 KB)
Products Immunodiagnostic

18/09/14 - 2:00

DiaSorin launches the stool test for Adenovirus on LIAISON (251.93 KB)
Products Immunodiagnostic

01/08/14 - 2:00

The Board of Directors approves the results for H1'14 (812.25 KB)
Financial Data

22/07/14 - 2:00

DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME (148.49 KB)
Financial Data

30/06/14 - 2:00

DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM (250.1 KB)
Products Immunodiagnostic

03/06/14 - 2:00

DiaSorin launches the test for Vitamin D 1,25 on LIAISON (265.57 KB)
Products Immunodiagnostic

09/05/14 - 2:00

The Board of Directors approves the results for Q1'14 (573.05 KB)
Financial Data

23/04/14 - 2:00

Shareholders' meeting approves FY Results 2013 (107.65 KB)
Financial Data

06/03/14 - 1:00

The Board of Directors approves the results for FY'13 (753.73 KB)
Financial Data

18/02/14 - 1:00

DiaSorin launches the new test for PTH on LIAISON (597.92 KB)
Products Immunodiagnostic

11/02/14 - 1:00

DiaSorin launches the test for Rotavirus on stool sample (573.97 KB)
Products Immunodiagnostic

28/01/14 - 1:00

DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018 (336.26 KB)
Acquisition / Partnership

24/01/14 - 1:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China (579.02 KB)
Products Immunodiagnostic

09/01/14 - 1:00

DiaSorin launches the test for Cytomegalovirus on LIAISON IAM (174.61 KB)
Products Immunodiagnostic

08/11/13 - 1:00

The Board of Directors approves the Q3'13 Results (766.57 KB)
Financial Data

29/10/13 - 1:00

DiaSorin signes a 5-year agreement with Roche (432.42 KB)
Acquisition / Partnership

25/10/13 - 2:00

DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)
Products Immunodiagnostic

10/10/13 - 2:00

DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)
Products Immunodiagnostic

24/09/13 - 2:00

DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)
Products Immunodiagnostic

01/08/13 - 2:00

The Board of Directors approves the results for the H1 '13 (386.67 KB)
Financial Data

24/07/13 - 2:00

DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)
Products

11/07/13 - 2:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)
Products Immunodiagnostic

28/06/13 - 2:00

DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)
Products Immunodiagnostic

20/06/13 - 2:00

DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)
Products Immunodiagnostic

10/05/13 - 2:00

The Board of Directors approves the results for Q1'13 (763.61 KB)
Financial Data

02/05/13 - 2:00

Compensation Commitee-Errata corrige (179.38 KB)
Financial Data

22/04/13 - 2:00

Shareholders' meeting approves FY Results 2012 (57.22 KB)
Financial Data

17/04/13 - 2:00

FDA approves the Aldosterone assay (439.58 KB)
Products Immunodiagnostic

02/04/13 - 2:00

DiaSorin signs an agreement with Seegene (243.64 KB)
Acquisition / Partnership

08/03/13 - 1:00

The BoD approves FY 2012 results (477.24 KB)
Financial Data

07/03/13 - 1:00

Notification of changes in share capital (46.86 KB)
Financial Data

07/03/13 - 1:00

Notice availability By-Laws (36.87 KB)
Financial Data

07/02/13 - 1:00

Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)
Products Immunodiagnostic

07/02/13 - 1:00

Notification of changes in share capital (46.89 KB)
Financial Data

07/02/13 - 1:00

Notice availability By-Laws (139.13 KB)
Financial Data

30/01/13 - 1:00

The Board of Directors approves the results for the FY '12 (477.24 KB)
Financial Data

29/01/13 - 1:00

Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)
Products Immunodiagnostic

20/12/12 - 1:00

Shareholders' meeting (55.42 KB)
Financial Data

07/11/12 - 1:00

The BoD approves Q3'12 results (280.42 KB)
Financial Data

03/08/12 - 2:00

The BoD approves H1'12 results (279.41 KB)
Financial Data

30/07/12 - 2:00

DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)
Acquisition / Partnership

27/06/12 - 2:00

Notification of changes in share capital (335.97 KB)
Financial Data

11/05/12 - 2:00

The BoD approves Q1'12 results (122.04 KB)
Financial Data

04/05/12 - 2:00

NorDiag acquisition (88.87 KB)
Acquisition / Partnership

23/04/12 - 2:00

2011 statutory financial statement approval (182.29 KB)
Financial Data

10/04/12 - 2:00

Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)
Products Immunodiagnostic

02/04/12 - 2:00

Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)
Products Immunodiagnostic

30/03/12 - 2:00

Financial calendar update (176.51 KB)
Financial Data

22/03/12 - 1:00

Stock options to employees (175.38 KB)
Financial Data

12/03/12 - 1:00

Agreement with Sonic Healthcare on Vitamin D (179.85 KB)
Acquisition / Partnership

09/03/12 - 1:00

The BoD approves FY 2011 results (357.11 KB)
Financial Data

07/03/12 - 1:00

Notification of changes in share capital (46.84 KB)
Financial Data

17/02/12 - 1:00

DiaSorin became a member of the ISBT (178.96 KB)
Acquisition / Partnership

09/02/12 - 1:00

Notice of change in share capital (46.97 KB)
Financial Data

02/02/12 - 1:00

FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)
Products Immunodiagnostic

27/01/12 - 1:00

2012 Financial calendar update (177.74 KB)
Financial Data

25/01/12 - 1:00

Dividend distribution in June (115.61 KB)
Financial Data

19/01/12 - 1:00

Prize for best Italian Company in R&D in the UK (183.95 KB)
Other

13/01/12 - 1:00

2012 Financial calendar (176.51 KB)
Financial Data

12/01/12 - 1:00

New anti HBs II (available outside the US and Canada only) (196.83 KB)
Products Immunodiagnostic

23/12/11 - 1:00

Financial instruments to employees (57.22 KB)
Financial Data

19/12/11 - 1:00

Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only) (192.66 KB)
Products Immunodiagnostic

19/11/11 - 1:00

Buy-back plan (35.47 KB)
Financial Data

18/11/11 - 1:00

Financial instruments to employees (56.82 KB)
Financial Data

11/11/11 - 1:00

The BoD approves Q3'11 results (334.35 KB)
Financial Data

28/10/11 - 2:00

Buy-back plan (103.99 KB)
Financial Data

25/10/11 - 2:00

Buy-back plan (104.72 KB)
Financial Data

18/10/11 - 2:00

Buy-back plan (136.18 KB)
Financial Data

17/10/11 - 2:00

2011-2015 Business Plan: a new business wave (195.1 KB)
Financial Data

10/10/11 - 2:00

New Chief Financial Officer (196.26 KB)
Other

06/10/11 - 2:00

Cardinal Health: agreement extended to 2014 (192.57 KB)
Acquisition / Partnership

04/10/11 - 2:00

Buy-back plan (204.92 KB)
Financial Data

01/09/11 - 2:00

Resignation of Chief Financial Officer (177.77 KB)
Other

31/08/11 - 2:00

2011 Financial calendar update (176.4 KB)
Financial Data

03/08/11 - 2:00

The BoD approves H1'11 results (324.48 KB)
Financial Data

11/07/11 - 2:00

Voluntarily removal from the STAR segment (194.93 KB)
Financial Data

13/05/11 - 2:00

The BoD approves Q1'11 results (307.28 KB)
Financial Data

11/05/11 - 2:00

DiaSorin and Labcorp extend strategic business relationship (100.01 KB)
Acquisition / Partnership

06/05/11 - 2:00

Agreement with Precision System Science Co., LTD (171.54 KB)
Acquisition / Partnership

28/04/11 - 2:00

The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution (175.61 KB)
Financial Data

16/03/11 - 1:00

The BoD approves FY'10 results (368.28 KB)
Financial Data

16/03/11 - 1:00

Dividend information amendment (159.83 KB)
Financial Data

28/02/11 - 1:00

2011 Financial calendar update (179.92 KB)
Financial Data

19/02/11 - 1:00

Notice of change in share capital (5.28 KB)
Financial Data

18/02/11 - 1:00

Buy-back plan (134.06 KB)
Financial Data

17/02/11 - 1:00

Financial instruments to employees (56.37 KB)
Financial Data

16/02/11 - 1:00

Buy-back plan (105.2 KB)
Financial Data

15/02/11 - 1:00

Buy-back plan (91.38 KB)
Financial Data

14/02/11 - 1:00

The BoD approves Q4'10 results (161 KB)
Financial Data

31/01/11 - 1:00

Buy-back plan (105.05 KB)
Financial Data

29/01/11 - 1:00

Buy-back plan (105.2 KB)
Financial Data

28/01/11 - 1:00

Buy-back plan (105.04 KB)
Financial Data

27/01/11 - 1:00

Buy-back plan (105.04 KB)
Financial Data

26/01/11 - 1:00

FDA approves the LIAISON XL (194.2 KB)
Products Immunodiagnostic

25/01/11 - 1:00

Buy-back plan (105.22 KB)
Financial Data

24/01/11 - 1:00

Buy-back plan (104.72 KB)
Financial Data

21/01/11 - 1:00

Buy-back plan (105.05 KB)
Financial Data

20/01/11 - 1:00

Buy-back plan (91.39 KB)
Financial Data

19/01/11 - 1:00

Buy-back plan (105.31 KB)
Financial Data

18/01/11 - 1:00

Buy-back plan (35.47 KB)
Financial Data

17/01/11 - 1:00

Buy-back plan (134.01 KB)
Financial Data

17/01/11 - 1:00

The Sonic Healthcare Group chooses DiaSorin (181.71 KB)
Acquisition / Partnership

16/01/11 - 1:00

2011 Financial calendar (179.49 KB)
Financial Data

22/12/10 - 1:00

2011 Financial calendar (180.28 KB)
Financial Data

20/12/10 - 1:00

Dividend may be distributed in June (445.78 KB)
Financial Data

02/12/10 - 1:00

Comment on position Paper on Vitamin D (53.46 KB)
Products Immunodiagnostic

24/11/10 - 1:00

Change in share capital (46.85 KB)
Financial Data

18/11/10 - 1:00

Financial instruments to employees (48.33 KB)
Financial Data

05/11/10 - 1:00

The BoD approves Q3'10 results (414.16 KB)
Financial Data

02/11/10 - 1:00

Change in share capital (313.61 KB)
Financial Data

08/10/10 - 2:00

2010 Financial calendar update (174.1 KB)
Financial Data

30/09/10 - 2:00

Change in share capital (5.25 KB)
Financial Data

24/09/10 - 2:00

Financial instruments to employees (48.81 KB)
Financial Data

16/09/10 - 2:00

Stock options exercised by key managers (195.67 KB)
Financial Data

02/09/10 - 2:00

Financial instruments to employees (24.27 KB)
Financial Data

06/08/10 - 2:00

The BoD approves H1'10 results (287.11 KB)
Financial Data

07/07/10 - 2:00

Agreement with Meridian Inc. (182.7 KB)
Acquisition / Partnership

06/07/10 - 2:00

2010 Financial calendar update (174.1 KB)
Financial Data

02/07/10 - 2:00

Financial instruments to employees (24.37 KB)
Financial Data

01/06/10 - 2:00

Acquisition of MUREX product line (102.6 KB)
Acquisition / Partnership

14/05/10 - 2:00

The BoD approves Q1'10 results (254.05 KB)
Financial Data

27/04/10 - 2:00

Approval of statutory financial statements (182.99 KB)
Financial Data

20/04/10 - 2:00

2010 Financial calendar update (168.23 KB)
Financial Data

14/04/10 - 2:00

Postponement of the term for lists of members of the Board of Auditors (40.34 KB)
Financial Data

09/04/10 - 2:00

China approves new prenatal screening product line on LIAISON (141.08 KB)
Products Immunodiagnostic

02/04/10 - 2:00

Financial instruments to employees (27.79 KB)
Financial Data

22/03/10 - 1:00

The BoD approves FY 2009 results (306.02 KB)
Financial Data

10/03/10 - 1:00

Acquisition of MUREX product line (45.5 KB)
Acquisition / Partnership

01/03/10 - 1:00

2010 Financial calendar update (192.49 KB)
Financial Data

12/02/10 - 1:00

The BoD approves Q4'09 results (213.8 KB)
Financial Data

18/01/10 - 1:00

2010 Financial calendar (103 KB)
Financial Data

24/12/09 - 1:00

Financial instruments to employees (26.76 KB)
Financial Data

30/10/09 - 1:00

The BoD approves Q3'09 results (212.92 KB)
Financial Data

12/10/09 - 2:00

Strengthening of group's R&D team (99.72 KB)
Other

08/10/09 - 2:00

2009 Financial calendar update (97.3 KB)
Financial Data

05/10/09 - 2:00

Financial instruments to employees (27.08 KB)
Financial Data

06/08/09 - 2:00

The BoD approves H1'09 results (214.79 KB)
Financial Data

08/06/09 - 2:00

2009 Financial calendar update (97.33 KB)
Financial Data

18/05/09 - 2:00

Financial instruments to employees (26.65 KB)
Financial Data

10/04/09 - 2:00

Corporate Governance Report at December 2008. (97.57 KB)
Financial Data

08/04/09 - 2:00

2009 Financial calendar update (103.88 KB)
Financial Data

19/03/09 - 1:00

The BoD approves FY 2008 results (221.59 KB)
Financial Data

20/02/09 - 1:00

Financial instruments to employees (26.39 KB)
Financial Data

13/02/09 - 1:00

The BoD approves Q4'08 results (170.79 KB)
Financial Data

28/01/09 - 1:00

2009 Financial calendar (93.96 KB)
Financial Data

08/01/09 - 1:00

FDA clearance to five LIAISON products (96.84 KB)
Products Immunodiagnostic

23/12/08 - 1:00

Financial instruments to employees (26.19 KB)
Financial Data

21/11/08 - 1:00

Financial instruments to employees (23.66 KB)
Financial Data

13/11/08 - 1:00

The BoD approves Q3'08 results (171.93 KB)
Financial Data

22/09/08 - 2:00

Agreement in Japan with Advanced Life Science Institute (99.16 KB)
Acquisition / Partnership

08/08/08 - 2:00

The BoD approves H1'08 results (194.3 KB)
Financial Data

09/07/08 - 2:00

Acquisition of Biotrin (99.08 KB)
Acquisition / Partnership

16/05/08 - 2:00

Financial instruments to employees (23.28 KB)
Financial Data

15/05/08 - 2:00

Results for Q1'08 (159.78 KB)
Financial Data

24/04/08 - 2:00

2007 statutory financial Statements approved (93.67 KB)
Financial Data

21/04/08 - 2:00

2008 Financial calendar update (93.56 KB)
Financial Data

19/03/08 - 1:00

The BoD approves FY 2007 results (198.25 KB)
Financial Data

14/02/08 - 1:00

The BoD approves Q4'07 results (170.91 KB)
Financial Data

29/01/08 - 1:00

2008 Financial calendar (88.78 KB)
Financial Data

07/01/08 - 1:00

Financial instruments to employees (29.51 KB)
Financial Data